Multidisciplinary considerations in the implementation of the findings from the American college of surgeons oncology group (ACOSOG) Z0011 study: A practice-changing trial

Annals of Surgical Oncology

Volumn 18, Issue 9, 2011, Pages 2407-2412

  Caudle, Abigail S ^a   Hunt, Kelly K ^a   Kuerer, Henry M ^a   Meric Bernstam, Funda ^a   Lucci, Anthony ^a   Bedrosian, Isabelle ^a   Babiera, Gildy V ^a   Hwang, Rosa F ^a   Ross, Merrick I ^a   Feig, Barry W ^a   Hoffman, Karen ^a   Litton, Jennifer K ^a   Sahin, Aysegul A ^a   Yang, Wei ^a   Hortobagyi, Gabriel N ^a   Buchholz, Thomas A ^a   Mittendorf, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); MICROMETASTASIS; MORBIDITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADENOCARCINOMA; AXILLA; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; NEOPLASTIC CELLS, CIRCULATING; SENTINEL LYMPH NODE BIOPSY;

EID: 80052758901     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1593-7     Document Type: Review

References (26)

1. A Giuliano D Kirgan J Guenther D Morton 1994 Lymphatic mapping and sentinel lymphadenectomy for breast cancer Ann Surg. 220 391 399 8092905 10.1097/00000658-199409000-00015 1:STN:280:DyaK2cznvFyksA%3D%3D
2. A Giuliano, et al. 1995 Improved axillary staging of breast cancer with sentinel lymphadenectomy Ann Surg. 222 394 399 7677468 10.1097/00000658- 199509000-00016 1:STN:280:DyaK2Mvgsl2ksw%3D%3D
3. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: breast, version 2.2008 (2008).
4. G Lyman, et al. 2006 American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer J Clin Oncol. 24 210 211 10.1200/JCO.2005.04.7670 (Pubitemid 46638825)
5. T Kim A Guiuliano G Lyman 2006 Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis Cancer. 106 4 16 16329134 10.1002/cncr.21568 (Pubitemid 43033320)
6. AJCC cancer staging manual. New York: Springer; 2009.
7. J Sosa, et al. 1998 Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer Ann Surg Oncol. 5 140 149 9527267 10.1007/BF02303847 1:STN:280:DyaK1c7os1CqtQ%3D%3D (Pubitemid 29071283)
8. P Cabanes, et al. 1992 Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie Lancet. 339 1245 1248 1349666 10.1016/0140-6736(92)91591-U 1:STN:280:DyaK383lt1GgsA%3D%3D
9. G Cserni, et al. 2004 Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer Br J Surg. 91 1245 1252 15376203 10.1002/bjs.4725 1:STN:280:DC%2BD2cvpsFehtQ%3D%3D (Pubitemid 39331448)
10. C van Deurzen, et al. 2008 Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node J Natl Cancer Inst. 100 1574 1580 19001602 10.1093/jnci/djn343
11. Yi M, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17.
12. K Bilimoria, et al. 2009 Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer J Clin Oncol. 27 2946 2953 19364968 10.1200/JCO.2008.19.5750
13. A Giuliano, et al. 2010 Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American college of surgeons oncology group Z0011 randomized trial Ann Surg. 252 426 432 20739842
14. A Giuliano KK Hunt KV Ballman PD Beitsch PW Whitworth PW Blumencranz AM Leitch S Saha LM McCall M Morrow 2011 Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial JAMA. 305 6 569 75 21304082 10.1001/jama.2011.90 1:CAS:528:DC%2BC3MXhvVymtrg%3D
15. J Reznik M Cicchetti B Degaspe T Fitzgerald 2005 Analysis of axillary coverage during tangential radiation therapy to the breast Int J Radiat Oncol Biol Phys. 61 163 168 15629607 10.1016/j.ijrobp.2004.04.065 (Pubitemid 40039118)
16. P Schlembach, et al. 2001 Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation Int J Radiat Oncol Biol Phys. 51 671 678 11597808 10.1016/S0360-3016(01)01684-4 1:STN:280:DC%2BD3MrltFGisQ%3D%3D
17. Leitch A, et al. Factors influencing accrual to ACOSOG Z011, a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer. J Clin Oncol. 2006; 25:601.
18. E Mittendorf, et al. 2008 Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients Ann Surg Oncol. 15 3369 3377 18815841 10.1245/s10434-008-0153-2
19. D Slamon W Godolphin L Jones, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science. 244 707 712 2470152 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D (Pubitemid 19147683)
20. D Slamon, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
21. J Albert, et al. 2010 Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer Int J Radiat Oncol Biol Phys. 77 1296 1302 20472353 10.1016/j.ijrobp. 2009.12.011 1:CAS:528:DC%2BC3cXovFCjur0%3D
22. M Piccart-Gebhart, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med. 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
23. E Romond, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med. 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
24. K Van Zee, et al. 2003 A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy Ann Surg Oncol. 10 1140 1151 14654469 10.1245/ASO.2003.03.015 (Pubitemid 40486808)
25. R Hwang, et al. 2003 Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer Ann Surg Oncol. 10 248 253 12679309 10.1245/ASO.2003.05.020 (Pubitemid 40486957)
26. Mittendorf E, et al. Size matters: incorporation of sentinel lymph node (SLN) metastasis size into a nomogram predicting non-SLN involvement in SLN-positive breast cancer patients. Cancer Res. 2010;70 (Suppl):117 s (Abstract PD106-108).